KDR, kinase insert domain receptor, 3791

N. diseases: 623; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature. 31243333 2019
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification. 29855279 2018
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE Mutations in KDR have been reported previously in angiosarcomas. 28056866 2017
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 Biomarker disease BEFREE Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. 27160228 2016
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE Likewise, activating mutations in the receptor tyrosine kinase KDR (VEGFR2) have been reported in angiosarcomas and non-small cell lung cancers; the KDR A1065T mutation is reported to be sensitive to VEGFR kinase inhibitors, and fibroblast growth factor receptor inhibitors are in trials. 25679062 2015
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE The p.T771R mutation was previously implicated in autophosphorylation of VEGFR2 and reported in angiosarcomas alongside other driver mutations. 26422291 2015
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 Biomarker disease BEFREE Recently, possible involvement of MYC and KDR has been documented in a subset of angiosarcomas of soft tissue. 25231439 2015
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE Together, these findings indicate that the PLCγ1-R707Q mutation causes constitutive activation of PLCγ1 and may represent an alternative way of activation of KDR/PLCγ1 signaling besides KDR activation in angiosarcomas, with implications for VEGF/KDR targeted therapies. 25252913 2014
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 GeneticVariation disease BEFREE KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. 19723655 2009
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 Biomarker disease CTD_human Carcinogenic susceptibility of rasH2 mice to troglitazone. 17569031 2007
CUI: C0018923
Disease: Hemangiosarcoma
Hemangiosarcoma
0.590 CausalMutation disease CGI